Last updated: May 27, 2026
VERELAN is a brand of verapamil hydrochloride, typically supplied in extended-release formats (commonly Verelan PM and Verelan). Supply is handled through a mix of branded manufacturers, contract manufacturers (CMOs), and API makers, with distribution flowing through US wholesalers and often multiple labelers for generic equivalents.
Because “VERELAN” is a dosage-form brand name rather than a single, unique product dossier, supplier mapping depends on the exact strength and release profile (for example, capsule extended-release versus other extended-release presentations). Without those specifics, any supplier list risks being incorrect.
Which companies supply VERELAN (verapamil) in the US market?
Quick answer: VERELAN is typically supplied by the branded product holder’s manufacturing network for the listed strengths, with additional production for authorized generics or generic verapamil ER products often coming from multiple manufacturers and relabelers.
What “suppliers” usually means for VERELAN in diligence work
For pharma supply and IP risk work, supplier intelligence is split into:
- Finished dosage form manufacturers (capsule/tablet and packaging)
- API manufacturers (verapamil hydrochloride)
- CMOs for scale-up (often production sites listed in regulatory filings or product manufacturing records)
- Labelers and distributors (US wholesaler supply chain)
Supplier identification methods used in market intelligence
High-confidence supplier lists usually come from:
- FDA Orange Book “Application No.” and “Applicant” records for specific NDCs
- FDA Drugs@FDA manufacturing history and labeler info by NDC
- Contract manufacturing site disclosures tied to the listed drug product
- Public quality/manufacturing records and facility listings linked to the product application
What is the Orange Book status of VERELAN and how does that affect who supplies it?
Quick answer: Orange Book status governs whether there are multiple applicants and authorized/generic supply streams for the same active moiety and strength. For ER products like VERELAN, there can be:
- branded supply only (if no approved AB-rated generics exist)
- or multiple AB-rated generics/authorized versions that materially expand the supplier set
How to translate Orange Book fields into a supplier map
For each VERELAN strength and NDC:
- Drug product applicant often corresponds to the primary branded labeler
- Manufacturer (site) maps to the final dosage form plant
- Listed patents can affect market entry and therefore the timing of new supply sources
Who makes the verapamil API used for VERELAN?
Quick answer: Verapamil hydrochloride API is produced by multiple chemical suppliers globally; however, the exact API supplier used for VERELAN at a given time is not reliably inferable without NDC-specific manufacturing record linkage.
Typical API sourcing patterns for verapamil ER brands
- API may come from long-term approved suppliers and change only with regulatory notifications
- ER capsule products often use specialized API specs and hold times tied to the finished formulation
Which VERELAN dosage strengths and presentations drive different supplier sets?
Quick answer: Different VERELAN presentations (for example, Verelan PM versus Verelan ER) and strength (mg) can have different NDCs and therefore different applicants and manufacturing sites.
Common diligence approach
- Build a strength-by-NDC grid
- For each NDC, extract:
- applicant/labeler
- dosage form and release type
- listed manufacturers by site
- whether AB-rated generics exist
What generic entry risks affect VERELAN supply and supplier churn?
Quick answer: If AB-rated generics exist or patents are challenged, the supply chain can shift toward additional manufacturers and authorized generics for the same strength. That can also change:
- procurement leverage
- lead times
- and the number of alternate CMO sites
Paragraph IV and ANDA timing effects (where present)
When challengers win and enter, buyers often see:
- new labelers
- additional manufacturing sites
- and price compression that can drive further supplier churn
How does VERELAN compare with other verapamil ER brands on supplier breadth?
Quick answer: Other verapamil ER branded products and authorized generics often show wider supplier breadth than a single origin brand because multiple ANDAs may reference the same route and excipient class, and some manufacturers produce across multiple labelers.
Commercial implication for sourcing
If VERELAN faces price competition from AB-rated generics, procurement teams typically expand:
- secondary sources
- buffer inventory
- and dual-site qualification for continuity of supply
Key takeaways
- “VERELAN” is a brand for verapamil extended-release and supplier identification must be NDC-specific to be accurate.
- High-confidence supplier lists for VERELAN require Orange Book and NDC-linked manufacturing records for each strength/presentation.
- API supplier attribution cannot be reliably assigned to a brand without NDC-specific manufacturing record linkage.
FAQs
- What information in FDA Orange Book is used to identify VERELAN manufacturing sites by NDC?
- How do VERELAN PM and VERELAN differ in supplier and regulatory product records?
- Can different strengths of VERELAN be manufactured at different facilities?
- Which documents or FDA databases are most reliable for mapping VERELAN labelers and applicants?
- How does generic competition change the number of manufacturing suppliers for verapamil ER products?
References
(No sources cited because the prompt does not include VERELAN NDCs, strengths, or presentation types required to produce a correct supplier list.)
